Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Plaque Psoriasis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 79 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Oruka Therapeutics, Inc.

Last updated on ClinicalTrials.gov

August 10, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites